{"date":"2026-07-02","count":21,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4169-2026-07-02-2241-csv580","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"22:41:53","subject":"本公司董事會決議通過放棄認購子公司台灣基因核酸新藥股份有限公司現金增資案","clause":"第51款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 22:41，「本公司董事會決議通過放棄認購子公司台灣基因核酸新藥股份有限公司現金增資案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-07-02-2142-1vd2dl0","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:42:07","subject":"代重要子公司Upsher-Smith Laboratories, LLC依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第三款公告申報","clause":"第23款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-07-02 21:42，「代重要子公司Upsher-Smith Laboratories, LLC依「公開發行公司資金貸與及背書保證處理準則」第二」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-07-02-2141-1dcud1c","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:41:29","subject":"本公司及子公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第一款公告","clause":"第23款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-07-02 21:41，「本公司及子公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第一款公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-07-02-2130-evpr8z","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:30:11","subject":"公告本公司完成美國馬里蘭州生物製劑CDMO營運資產收購案","clause":"第51款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-07-02 21:30，「公告本公司完成美國馬里蘭州生物製劑CDMO營運資產收購案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-2120-1499eb","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:20:55","subject":"公告本公司第六屆薪資報酬暨提名委員會委員及薪資報酬暨提名委員會召集人","clause":"第6款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 21:20，「公告本公司第六屆薪資報酬暨提名委員會委員及薪資報酬暨提名委員會召集人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-2120-1y3zdzl","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:20:26","subject":"本公司董事會決議通過與子公司TCM Life Science Inc.簽署U101專屬授權合約","clause":"第20款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 21:20，「本公司董事會決議通過與子公司TCM Life Science Inc.簽署U101專屬授權合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-2120-1jenwtt","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"21:20:00","subject":"公告本公司董事會委任第二屆永續發展委員會委員","clause":"第6款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 21:20，「公告本公司董事會委任第二屆永續發展委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4114-2026-07-02-1834-1mnxco3","company_id":"4114","company":"健喬","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"18:34:00","subject":"公告本公司現金及股票股利配發基準日及調整配股配息率","clause":"第14款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：健喬（4114），2026-07-02 18:34，「公告本公司現金及股票股利配發基準日及調整配股配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2026-07-02-1808-1v1fzr4","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"18:08:48","subject":"衛生福利部核准向榮生技之源自人體脂肪間質幹細胞外泌體(Exosomes)得為化粧品成份","clause":"第51款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2026-07-02 18:08，「衛生福利部核准向榮生技之源自人體脂肪間質幹細胞外泌體(Exosomes)得為化粧品成份」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4190-2026-07-02-1752-1d8juip","company_id":"4190","company":"佐登-KY","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"17:52:13","subject":"公告本公司中華民國境內第四次有擔保轉換公司債之發行，已依中國證監會發布之『境內企業境外發行證券和上市管理試行辦法』進行備案","clause":"第51款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：佐登-KY（4190），2026-07-02 17:52，「公告本公司中華民國境內第四次有擔保轉換公司債之發行，已依中國證監會發布之『境內企業境外發行證券和上市管理試行辦法』進行備」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6810-2026-07-02-1746-p9bs5i","company_id":"6810","company":"新穎生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-02","time":"17:46:22","subject":"公告本公司重要營運主管異動","clause":"第11款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：新穎生醫（6810），2026-07-02 17:46，「公告本公司重要營運主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6496-2026-07-02-1738-90lz2","company_id":"6496","company":"科懋","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"17:38:42","subject":"本公司註銷員工權利新股減資變更登記完成","clause":"第36款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：科懋（6496），2026-07-02 17:38，「本公司註銷員工權利新股減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4747-2026-07-02-1726-fahib5","company_id":"4747","company":"強生*","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"17:26:54","subject":"(補充115/6/26公告-其他敘明事項)本公司以股份轉換方式處分所持健亞全部股份，並取得易威新發行普通股","clause":"第20款","fact_date":"2026-05-05","cite_as":"公開資訊觀測站重大訊息：強生*（4747），2026-07-02 17:26，「(補充115/6/26公告-其他敘明事項)本公司以股份轉換方式處分所持健亞全部股份，並取得易威新發行普通股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-1646-v1gwxu","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"16:46:11","subject":"公告本公司調整現金股利配息率","clause":"第14款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 16:46，「公告本公司調整現金股利配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3184-2026-07-02-1620-xlfvyz","company_id":"3184","company":"微邦","market":"興櫃","industry":"生技醫療","date":"2026-07-02","time":"16:20:17","subject":"公告本公司實施買回已發行股份事宜已執行完畢","clause":"第41款","fact_date":"2026-07-01","cite_as":"公開資訊觀測站重大訊息：微邦（3184），2026-07-02 16:20，「公告本公司實施買回已發行股份事宜已執行完畢」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-1614-1y3zdzl","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"16:14:40","subject":"本公司董事會決議通過與子公司TCM Life Science Inc.簽署U101專屬授權合約","clause":"第10款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 16:14，「本公司董事會決議通過與子公司TCM Life Science Inc.簽署U101專屬授權合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-07-02-1614-1j46v82","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"16:14:25","subject":"公告本公司現金股利除息基準日","clause":"第14款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-07-02 16:14，「公告本公司現金股利除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-07-02-1559-1609k5a","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"15:59:34","subject":"公告本公司永續發展委員會委員異動","clause":"第6款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-07-02 15:59，「公告本公司永續發展委員會委員異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6767-2026-07-02-1551-1saq0e8","company_id":"6767","company":"台微醫","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"15:51:51","subject":"本公司之Tripod-Fix可擴張椎體強化系統取得新加坡衛生科學局(HSA)上市銷售許可。","clause":"第53款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：台微醫（6767），2026-07-02 15:51，「本公司之Tripod-Fix可擴張椎體強化系統取得新加坡衛生科學局(HSA)上市銷售許可。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2026-07-02-1507-mr1837","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2026-07-02","time":"15:07:16","subject":"公告本公司副總經理暨研發主管異動","clause":"第8款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2026-07-02 15:07，「公告本公司副總經理暨研發主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2026-07-02-1419-p67uuk","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2026-07-02","time":"14:19:16","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2026-07-02 14:19，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}